vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and GENCOR INDUSTRIES INC (GENC). Click either name above to swap in a different company.
GENCOR INDUSTRIES INC is the larger business by last-quarter revenue ($23.6M vs $20.0M, roughly 1.2× AGIOS PHARMACEUTICALS, INC.). GENCOR INDUSTRIES INC runs the higher net margin — 14.6% vs -541.1%, a 555.7% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs -25.0%). GENCOR INDUSTRIES INC produced more free cash flow last quarter ($10.1M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs -23.9%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Gencor Industries Inc is a leading manufacturer of heavy construction and infrastructure equipment, specializing in asphalt production plants, thermal combustion systems, and supporting road-building machinery. It primarily serves North American and global construction markets, supplying products to both public sector infrastructure projects and private commercial construction operators.
AGIO vs GENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $23.6M |
| Net Profit | $-108.0M | $3.4M |
| Gross Margin | 90.6% | 28.7% |
| Operating Margin | -608.9% | 13.2% |
| Net Margin | -541.1% | 14.6% |
| Revenue YoY | 86.1% | -25.0% |
| Net Profit YoY | -11.9% | -9.8% |
| EPS (diluted) | $-1.86 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | $23.6M | ||
| Q3 25 | $12.9M | $18.8M | ||
| Q2 25 | $12.5M | $27.0M | ||
| Q1 25 | $8.7M | $38.2M | ||
| Q4 24 | $10.7M | $31.4M | ||
| Q3 24 | $9.0M | $20.9M | ||
| Q2 24 | $8.6M | $25.6M | ||
| Q1 24 | $8.2M | $40.7M |
| Q4 25 | $-108.0M | $3.4M | ||
| Q3 25 | $-103.4M | $1.9M | ||
| Q2 25 | $-112.0M | $3.8M | ||
| Q1 25 | $-89.3M | $6.1M | ||
| Q4 24 | $-96.5M | $3.8M | ||
| Q3 24 | $947.9M | $1.5M | ||
| Q2 24 | $-96.1M | $2.6M | ||
| Q1 24 | $-81.5M | $6.2M |
| Q4 25 | 90.6% | 28.7% | ||
| Q3 25 | 87.0% | 24.2% | ||
| Q2 25 | 86.3% | 26.5% | ||
| Q1 25 | 87.6% | 29.7% | ||
| Q4 24 | 88.3% | 27.6% | ||
| Q3 24 | 91.3% | 25.6% | ||
| Q2 24 | 82.6% | 23.9% | ||
| Q1 24 | 92.3% | 30.3% |
| Q4 25 | -608.9% | 13.2% | ||
| Q3 25 | -907.4% | -1.2% | ||
| Q2 25 | -1020.1% | 11.6% | ||
| Q1 25 | -1222.0% | 17.0% | ||
| Q4 24 | -1165.3% | 14.7% | ||
| Q3 24 | -1146.9% | 5.9% | ||
| Q2 24 | -1228.3% | 7.8% | ||
| Q1 24 | -1124.3% | 17.4% |
| Q4 25 | -541.1% | 14.6% | ||
| Q3 25 | -803.1% | 10.2% | ||
| Q2 25 | -899.4% | 14.2% | ||
| Q1 25 | -1023.3% | 16.0% | ||
| Q4 24 | -899.6% | 12.1% | ||
| Q3 24 | 10574.7% | 6.9% | ||
| Q2 24 | -1115.7% | 10.0% | ||
| Q1 24 | -995.8% | 15.3% |
| Q4 25 | $-1.86 | $0.23 | ||
| Q3 25 | $-1.78 | $0.13 | ||
| Q2 25 | $-1.93 | $0.26 | ||
| Q1 25 | $-1.55 | $0.42 | ||
| Q4 24 | $-1.44 | $0.26 | ||
| Q3 24 | $16.22 | $0.10 | ||
| Q2 24 | $-1.69 | $0.17 | ||
| Q1 24 | $-1.45 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $147.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $215.2M |
| Total Assets | $1.3B | $228.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | $147.7M | ||
| Q3 25 | $92.7M | $136.3M | ||
| Q2 25 | $80.9M | $136.0M | ||
| Q1 25 | $79.0M | $143.7M | ||
| Q4 24 | $76.2M | $130.1M | ||
| Q3 24 | $253.7M | $115.4M | ||
| Q2 24 | $84.5M | $116.6M | ||
| Q1 24 | $118.8M | $117.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $215.2M | ||
| Q3 25 | $1.3B | $211.8M | ||
| Q2 25 | $1.4B | $209.9M | ||
| Q1 25 | $1.5B | $206.1M | ||
| Q4 24 | $1.5B | $200.0M | ||
| Q3 24 | $1.6B | $196.1M | ||
| Q2 24 | $660.5M | $194.7M | ||
| Q1 24 | $743.9M | $192.1M |
| Q4 25 | $1.3B | $228.9M | ||
| Q3 25 | $1.4B | $222.6M | ||
| Q2 25 | $1.5B | $220.2M | ||
| Q1 25 | $1.6B | $223.9M | ||
| Q4 24 | $1.7B | $218.2M | ||
| Q3 24 | $1.8B | $208.1M | ||
| Q2 24 | $773.1M | $201.8M | ||
| Q1 24 | $849.7M | $206.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $11.1M |
| Free Cash FlowOCF − Capex | $-97.3M | $10.1M |
| FCF MarginFCF / Revenue | -487.5% | 43.0% |
| Capex IntensityCapex / Revenue | 5.6% | 4.1% |
| Cash ConversionOCF / Net Profit | — | 3.23× |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | $-3.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | $11.1M | ||
| Q3 25 | $-88.2M | $-275.0K | ||
| Q2 25 | $-77.1M | $-23.9M | ||
| Q1 25 | $-111.5M | $12.4M | ||
| Q4 24 | $-133.2M | $14.8M | ||
| Q3 24 | $-84.2M | $-3.2M | ||
| Q2 24 | $-72.6M | $-1.0M | ||
| Q1 24 | $-99.9M | $11.7M |
| Q4 25 | $-97.3M | $10.1M | ||
| Q3 25 | $-89.7M | $-1.3M | ||
| Q2 25 | $-78.0M | $-24.4M | ||
| Q1 25 | $-112.3M | $12.3M | ||
| Q4 24 | $-134.1M | $14.5M | ||
| Q3 24 | $-84.6M | $-3.3M | ||
| Q2 24 | $-72.7M | $-1.4M | ||
| Q1 24 | $-100.0M | $11.7M |
| Q4 25 | -487.5% | 43.0% | ||
| Q3 25 | -696.5% | -6.8% | ||
| Q2 25 | -626.2% | -90.4% | ||
| Q1 25 | -1286.4% | 32.2% | ||
| Q4 24 | -1250.1% | 46.1% | ||
| Q3 24 | -944.2% | -15.8% | ||
| Q2 24 | -844.4% | -5.6% | ||
| Q1 24 | -1221.2% | 28.7% |
| Q4 25 | 5.6% | 4.1% | ||
| Q3 25 | 12.1% | 5.4% | ||
| Q2 25 | 7.0% | 1.8% | ||
| Q1 25 | 8.8% | 0.4% | ||
| Q4 24 | 9.0% | 1.0% | ||
| Q3 24 | 4.7% | 0.4% | ||
| Q2 24 | 1.8% | 1.5% | ||
| Q1 24 | 1.7% | 0.0% |
| Q4 25 | — | 3.23× | ||
| Q3 25 | — | -0.14× | ||
| Q2 25 | — | -6.24× | ||
| Q1 25 | — | 2.04× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | -0.09× | -2.22× | ||
| Q2 24 | — | -0.41× | ||
| Q1 24 | — | 1.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
